Description
Key facts
Cell type:RAW 264.7,
Species or organism:Mouse,
Tissue:Lymphatic,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 104 bp deletion in exon 2,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CX3CR1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CX3CR1 also known as fractalkine receptor is a seven-transmembrane G protein-coupled receptor. It has a molecular weight of about 40 kDa. This receptor is expressed in various tissues particularly on immune cells like monocytes natural killer cells T cells and microglia. CX3CR1 binds to its ligand CX3CL1 or fractalkine which is a chemokine involved in directing cell movement. The receptor-ligand interaction is critical for the adhesion and migration of leukocytes to inflammatory sites.
Biological function summary
CX3CR1 plays a significant role in immune regulation and cellular migration. It is not part of a larger protein complex but interacts directly with monocyte and microglia cells influencing their activity. CX3CR1 is recognized as a marker for microglia in flow cytometry applications assisting in the identification of these brain-resident immune cells. The receptor is frequently studied using monoclonal antibodies like anti-CX3CR1 and is subject to inhibition by CX3CR1 antagonists such as 8e10 affecting its function in immune responses.
Pathways
CX3CR1 involves itself heavily in the chemokine signaling pathway and the inflammatory response pathway. Its interaction with CX3CL1 influences the PI3K-Akt signaling pathway modulating cell survival and proliferation. The receptor works in conjunction with CCR2 in monocyte navigation impacting the inflammatory cascade during immune response. Their coordinated action is important for cellular trafficking to sites requiring immune intervention.
CX3CR1 has associations with neurodegenerative diseases such as Alzheimer's disease as well as with atherosclerosis. Changes in its expression and function can exacerbate these conditions. In Alzheimer's disease microglial CX3CR1 may mediate neuroinflammatory processes affecting plaque buildup. In atherosclerosis the receptor is involved in monocyte recruitment to plaques influenced by the related protein fractalkine. Understanding these relationships provides insights into potential therapeutic targets for modulating disease progression.
